The Russian Health Ministry has authorized phase 1 and 2 clinical trials of EpiVacCorona-N, one more coronavirus vaccine developed by the Vector research center, according to the ministry’s register, Sputnik News reports.
“An open study of the safety, tolerability, reactogenicity and immunizing power of the EpiVacCorona-N peptide antigen-based vaccine for preventing COVID, involving volunteers aged 18-60 (phase 1-2),” the register read.
The trials started on April 8 and are set to end on September 30.
The EpiVacCorona vaccine, developed by the Vector State Research Center of Virology and Biotechnology, is a peptide-based drug that relies on a promising synthetic platform. It consists of artificially synthesized short fragments of viral proteins – peptides, through which the immune system learns how to recognize and then neutralize the virus.
